GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Nov 1, 2025

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001104659-25-118458General Corporate
Capex intensity50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.05% · OPTIONAL · VALID

Operating cash generation10thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

0.20% · OPTIONAL · VALID

Revenue growth60thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

12.95% · CORE · VALID

Gross margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

40.44% · CORE · VALID

Operating margin10thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

10.83% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Increased
Previous
2.76%
Current
3.05%
Delta
0.29%
Cash Generation Decreased
Previous
3.46%
Current
0.20%
Delta
-3.26%
Growth Increased
Previous
9.26%
Current
12.95%
Delta
3.68%
Margin Increased
Previous
39.15%
Current
40.44%
Delta
1.29%
Profitability Decreased
Previous
12.37%
Current
10.83%
Delta
-1.54%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.